Search clinical trials for: Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab)

Total 7 results

Medical College of Wisconsin

Active, not recruiting

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Hospices Civils de Lyon

Completed

Cystic Fibrosis Related Diabetes Screening. (D2M)

Cystic Fibrosis-related Diabetes
Ramathibodi Hospital

Completed

Three-level Injection Paravertebral Block vs General Anesthesia in Mastectomy

Radical Mastectomy

Thailand
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Lymphoblastic Lymphoma | Mixed Phenotype Acute Leukemia

United States, Canada, Australia, Puerto Rico, New Zealand

Search clinical trials for: Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations